Tcg Labs

Emerging manager

SEC exempt reporting adviser (venture capital exemption).

Website: https://www.tcglsoleil.com/
HQ: CA

TCG Labs Soleil is building a venture-biotech model in collaboration with The Column Group, combining a dedicated venture fund with an evergreen R&D hub. The team includes Managing Partners Jin-Long Chen, PhD, Tim Kutzkey, PhD, and Peter Svennilson, MBA, along with partners, principals, and other team members.

01 · Says / Does

Tag	Says	Does
Stages	Not stated	Not enough dated deals
Sectors	Biotech	Not enough dated deals
Regions	Not stated	Not enough dated deals

Says: what the firm's funds state. Does: from 0 dated deals in the last 24 months.

02 · Fund history

Fund	Year	Size	Status
TCG Labs Fund I, LP Funds, forms and oversees independent biotech portfolio companies, each built around a single-asset therapy for serious diseases. Guides programs from ideation to clinical proof of concept, then positions them for strategic partnerships. Inferred from the firm's website and portfolio companies	approx. 2023	$400M to $403.56M (Form D and SEC adviser filing)	Open, writing first checks

03 · People across funds

Aadit Shah, Principal
TCG Labs Fund I, LP (Team)
Dimitre Simeonov, PhD, Associate
TCG Labs Fund I, LP (Team)
Eric Gomez, PhD, Principal
TCG Labs Fund I, LP (Team)
Jin-Long Chen, PhD, Managing Partner
TCG Labs Fund I, LP (Team)
Kenneth A Clark, JD, Partner
TCG Labs Fund I, LP (Team)
Levi Smith, PharmD, PhD, Principal
TCG Labs Fund I, LP (Team)
Peter Svennilson, MBA, Managing Partner
TCG Labs Fund I, LP (Team)
Stephen Ruiz, PhD, Analyst
TCG Labs Fund I, LP (Team)
Tim Kutzkey, PhD, Managing Partner
TCG Labs Fund I, LP (Team)

04 · Recent deals

No dated deals found yet.

05 · Latest from the firm

No news from the firm's website yet.

06 · Sources

Fund dates and sizes are from SEC Form D filings.

Last verified: Oct 28, 2026